Genentech Xanelim Therapy Transition Study To Support Product Launch
Executive Summary
Genentech plans to generate data on transitioning patients from its psoriasis therapy Xanelim to other products to assist with efalizumab promotions upon approval.
You may also be interested in...
Genentech Will Focus On Pipeline For Near-Term Growth, CEO Says
Genentech's near-term growth will be based on its product pipeline rather than through acquisitions, CEO Arthur Levinson, PhD, told analysts during the company's fourth quarter earnings call Jan. 16
Genentech Will Focus On Pipeline For Near-Term Growth, CEO Says
Genentech's near-term growth will be based on its product pipeline rather than through acquisitions, CEO Arthur Levinson, PhD, told analysts during the company's fourth quarter earnings call Jan. 16
Xanelim BLA filing
Genentech and Xoma will conduct an additional pharmacokinetics study to confirm equivalence between Xanelim (efalizumab) material used for clinical testing and commercial lots. The trial will delay the estimated BLA filing date until summer 2002. Genentech had planned to file a BLA in the first quarter of 2002 (1"The Pink Sheet" Aug. 6, p. 20)